Dashboard
Manage Tickers

ABBVAbbVie Inc.

NYSE abbvie.com


$ 185.14 $ 2.99 (1.64 %)    

Friday, 26-Jul-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.29 $ 4.70 (1.03 %)
DIA $ 406.08 $ 6.48 (1.62 %)
SPY $ 544.34 $ 6.03 (1.12 %)
TLT $ 93.03 $ 0.72 (0.78 %)
GLD $ 220.60 $ 2.30 (1.05 %)
$ 185.16
$ 166.83 x 100
-- x --
-- - --
$ 132.11 - $ 186.85
6,948,832
na
328.29B
$ 0.63
$ 54.78
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-17-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-18-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-02-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 02-19-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-04-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 02-21-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-05-2019 06-30-2019 10-Q
21 05-03-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-20-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growth-expectations
AbbVie Wins Analyst Confidence with Q2 Bea...
07/26/2024 18:54:10

AbbVie reports Q2 earnings with adjusted EPS of $2.65, surpassing expectations. Net revenues hit $14.46 billion, reflecting a 4...

cantor-fitzgerald-reiterates-overweight-on-abbvie-maintains-200-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/26/2024 17:24:11

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

lockheed-martin-to-rally-over-14-here-are-10-top-analyst-forecasts-for-friday
Lockheed Martin To Rally Over 14%? Here Ar...
07/26/2024 14:27:18

truist-securities-reiterates-buy-on-abbvie-raises-price-target-to-210
Truist Securities Reiterates Buy on AbbVie...
07/26/2024 12:48:11

Truist Securities analyst Robyn Karnauskas reiterates AbbVie (NYSE:ABBV) with a Buy and raises the price target from $195 to...

wells-fargo-maintains-overweight-on-abbvie-raises-price-target-to-205
Wells Fargo Maintains Overweight on AbbVie...
07/26/2024 12:43:10

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $200 to $205.

barclays-maintains-overweight-on-abbvie-raises-price-target-to-200
Barclays Maintains Overweight on AbbVie, R...
07/26/2024 11:39:04

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $187 to $200.

abbvie-gains-eu-approval-for-skyrizi-to-treat-moderately-to-severely-active-ulcerative-colitis-in-adults
AbbVie Gains EU Approval For SKYRIZI To Tr...
07/26/2024 06:48:21

The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The appro...

stocks-rebound-as-us-economy-flexes-muscles-small-caps-rally-gold-falls-whats-driving-markets-thursday
Stocks Rebound As US Economy Flexes Muscle...
07/25/2024 17:00:09

Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last q...

abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and-cancer-drugs
AbbVie's Q2 Earnings Beat Estimates, Raise...
07/25/2024 14:18:07

AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sal...

abbvie-exec-announces-discontinuation-of-further-development-of-experimental-alzheimers-drug-abbv-916-as-standalone-antibody
AbbVie Exec Announces Discontinuation Of F...
07/25/2024 13:37:54

- Conference Call

abbvie-raises-2024-adjusted-diluted-eps-guidance-from-1061-1081-to-1071-1091-versus-consensus-of-1078-which-includes-an-unfavorable-impact-of-060-per-share-related-to-acquired-iprd-and-milestones-expense-incurred-year-to-date-through-q2-2024
AbbVie Raises 2024 Adjusted Diluted EPS Gu...
07/25/2024 11:39:21

abbvie-q2-2024-adj-eps-265-beats-257-estimate-sales-14462b-beat-14027b-estimate
AbbVie Q2 2024 Adj EPS $2.65 Beats $2.57 E...
07/25/2024 11:37:45

nasdaq-sp-futures-slide-on-more-negative-tech-tidings-as-focus-shifts-to-q2-gdp-data-strategist-says-trump-trades-may-not-work-even-if-ex-president-retakes-white-house
Nasdaq, S&P Futures Slide On More Negative...
07/25/2024 11:23:10

Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead t...

abbvie-earnings-preview-will-humiras-expiry-new-ceo-fuel-a-bullish-surge
AbbVie Earnings Preview: Will Humira's Exp...
07/24/2024 14:16:04

AbbVie will report Q2 earnings on Thursday. Investors watch for Humira impact and signs of recovery under new CEO.

abbvie-says-canadas-drug-agency-has-issued-its-first-ever-time-limited-reimbursement-recommendation-for-epkinly-epcoritamab
AbbVie Says Canada's Drug Agency Has Issue...
07/23/2024 11:05:00

This recommendation recognizes the unmet need of adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R ...

tesla-alphabet-gm-ford-lead-earnings-parade-this-week-as-market-struggles-to-sustain-the-summer-rally
Tesla, Alphabet, GM, Ford Lead Earnings Pa...
07/21/2024 21:18:25

The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.

peeling-back-the-layers-exploring-abbvie-through-analyst-insights
Peeling Back The Layers: Exploring AbbVie ...
07/19/2024 17:00:14

bmo-capital-maintains-outperform-on-abbvie-raises-price-target-to-214
BMO Capital Maintains Outperform on AbbVie...
07/19/2024 14:41:24

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $18...

100-invested-in-this-stock-5-years-ago-would-be-worth-300-today
$100 Invested In This Stock 5 Years Ago Wo...
07/18/2024 15:00:31

abbvie-unusual-options-activity
AbbVie Unusual Options Activity
07/17/2024 17:01:10

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)